[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100610745":3},{"organization":4,"armGroups":7,"interventions":16,"overallOfficials":11,"centralContacts":11,"locations":11,"responsibleParty":31,"collaborators":11,"id":35,"slug":36,"hasResults":37,"nctId":38,"briefTitle":39,"officialTitle":40,"acronym":11,"eligibilityCriteria":41,"healthyVolunteers":37,"sex":42,"minAge":43,"maxAge":11,"enrollmentInfo":44,"targetDuration":11,"studyType":47,"phases":48,"briefSummary":50,"conditions":51,"keywords":11,"overallStatus":55,"whyStopped":11,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":11},{"fullName":5,"class":6},"Sun Yat-sen University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Preoperative Stereotactic body radiotherapy and Tislelizumab (immunotherapy) plus Anlotinib","EXPERIMENTAL",null,[13,14,15],"Radiation: SBRT","Drug: Immunotherapy","Drug: antiangiogenesis therapy",[17,22,27],{"type":18,"name":19,"description":20,"armGroupLabels":21,"otherNames":11},"RADIATION","SBRT","SBRT 8Gy\\*3",[9],{"type":23,"name":24,"description":25,"armGroupLabels":26,"otherNames":11},"DRUG","Immunotherapy","Tislelizumab (immunotherapy) 200mg Q3W",[9],{"type":23,"name":28,"description":29,"armGroupLabels":30,"otherNames":11},"antiangiogenesis therapy","Anlotinib 8mg D1-D14 Q3W",[9],{"type":32,"investigatorFullName":33,"investigatorTitle":34,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"PRINCIPAL_INVESTIGATOR","Jianhua Fu","Professor","100610745","phase-2-neoadjuvant-sbrt-and-tislelizumab-immunotherapy-plus-anlotinib-for-resectable-egfr-wild-type-nsclc-100610745",false,"NCT07231575","Neoadjuvant SBRT and Tislelizumab (Immunotherapy) Plus Anlotinib for Resectable EGFR Wild-type NSCLC","Preoperative Stereotactic Body Radiotherapy and Tislelizumab (Immunotherapy) Plus Anlotinib for Operable Stage IB to III EGFR Wild-type Non-small Cell Lung Cancer（STATION）","Inclusion Criteria:\n\n1.18 years or older 2. Eastern Cooperative Oncology Group performance status: 0 or 1 3. Clinical stage IB to IIIB (T3-4N2) Resectable NSCLC 4. Adequate cardiopulmonary and haematological function.\n\nExclusion Criteria:\n\n1. Known EGFR-sensitising mutations and EML4-ALK fusions\n2. Concomitant malignancy, history of another cancer within the past 3 years.\n3. Current or previous use of immunosuppressive medication,active autoimmune disease, and interstitial lung disease or idiopathic pulmonary fibrosis on a screening radiographic scan","ALL","18 Years",{"count":45,"type":46},39,"ESTIMATED","INTERVENTIONAL",[49],"PHASE2","The neoadjuvant strategy of immunotherapy combined with chemotherapy has been recommended for resectable or potentially resectable tumors without driver-gene alterations.However, the AE of chemotherapy is more than 40%，which bring fear to the patients，especially for those who cannot tolerate or refuse chemotherapy.Several studies indicated that the strategies of chemo-free ,such as the combination of immunotherapy with antiangiogenic therapy or with SBRT, were safe and well tolerated, without increasing adverse reactions. Both of them have a promising efficacy with a manageable toxicity profile in patients with resectable NSCLC. The investigators aim to assess the activity and safety of neoadjuvant SBRT and immunotherapy plus antiangiogenic therapy in patients with resectable NSCLC.",[52,53,54],"Neoadjuvant Immunotherapy","NSCLC","Chemo-free Therapy","NOT_YET_RECRUITING","2025-11-15",{"date":58,"type":59},"2025-11-18","ACTUAL",{"date":61,"type":46},"2025-11-10",{"date":63,"type":46},"2032-05-30",{"name":5,"class":6}]